Satellos Bioscience (MSLE) Assets Average (2024 - 2026)
Satellos Bioscience (MSLE) posted quarterly Assets Average of $53.6 million for Q1 2026, up 26.3% quarter-over-quarter from $42.4 million in Q4 2024.
Satellos Bioscience (MSLE) Assets Average (2024 - 2026) Analysis & Trends
Satellos Bioscience (MSLE) has reported Assets Average for 2 consecutive years, with $53.6 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Assets Average changed N/A year-over-year to $53.6 million; the TTM figure through Mar 2026 stood at $53.6 million (changed N/A YoY), while the FY2025 annual figure was $41.3 million, down 1.9% from the prior year.
- Assets Average grew to $53.6 million in Q1 2026 per MSLE's latest filing, from $42.4 million in the prior quarter.
- Across five years, Assets Average topped out at $53.6 million in Q1 2026 and bottomed at $42.4 million in Q4 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Assets Avg. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 26.95 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 41.30 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | - |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 11.22 Bn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 8.86 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 5.34 Bn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 2.09 Bn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 19.82 Bn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 25.27 Bn |
| 10 | Satellos Bioscience | 208.31 Mn | 208.31 Mn | - | 70.50 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 53.56 Mn |
| Dec 31, 2024 | 42.40 Mn |